Malignant Hepatobiliary Neoplasm

The frequent deletion of PBLD in HCC tissues is an independent predictor of poor prognosis for patients with HCC. Elevated PBLD expression has been show to reduce the growth and spread of HCC.

PMID 26594798 · Li et al., 2016 · Open in CIViC

In biliary tract cancer (BTC) models with PBRM1 loss-of-function (EGI1 and CCC5), sensitivity to PARP inhibitors increased significantly, with lower IC50 values for niraparib (2.25 µM vs 6.62 µM, p = … (full text at CIViC)

PMID 37400502 · Zimmer et al., 2023 · Open in CIViC

CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) wer… (full text at CIViC)

PMID 22596232 · Hagiwara et al., 2012 · Open in CIViC

SHP-1 has been shown to be a tumor suppressor in hematopoietic cancers. Reduced SHP-1 expression in HCC correlates to aggressive tumor behavior resulting in a poor prognosis for patients.

PMID 29776962 · Wen et al., 2018 · Open in CIViC

Through the histological examination of 25 patient tumor samples with hepatocellular carcinoma, the efficacy of postoperative sorafenib treatment may be correlated with higher levels of c-Raf-1 expres… (full text at CIViC)

PMID 26981887 · Lei et al., 2016 · Open in CIViC

Phase 2 trial of adult hepatocellular patients treated with sunitinib analyzed how baseline concentration of different soluble VEGF proteins predict overall survival (OS) and time to progression (TTP)… (full text at CIViC)

PMID 21787417 · Harmon et al., 2011 · Open in CIViC

In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, two patient with cholangiocarcinoma with NTRK fusion was enrolled. One of the two patient showed PR.

PMID 29466156 · Drilon et al., 2018 · Open in CIViC